Dung T. Le, MD, on Gastric or Gastroesophageal Junction Cancer: Results From the CheckMate-032 Trial
2016 Gastrointestinal Cancers SymposiumDung T. Le, MD, from Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, discusses study findings on the safety and activity of nivolumab monotherapy in advanced and metastatic gastric or gastroesophageal junction cancer (Abstract 6).
Related Videos
Heinz-Josef Lenz, MD, on Metastatic Colorectal Cancer: Results of the MAVERICC Study
Heinz-Josef Lenz, MD, of the USC Norris Comprehensive Cancer Center, discusses the findings of this phase II study of mFOLFOX6/bevacizumab vs FOLFIRI/bevacizumab with biomarker str...
James L. Abbruzzese, MD, on Pancreatic Cancer: Expert Perspective
James L. Abbruzzese, MD, of Duke University, discusses the international outlook on patterns of care and their impact on outcomes.
Heinz-Josef Lenz, MD, on Metastatic Colorectal Cancer: Results of the MAVERICC Study (German Language Version)
Heinz-Josef Lenz, MD, of the USC Norris Comprehensive Cancer Center, discusses in German the findings of this phase II study of mFOLFOX6/bevacizumab vs FOLFIRI/bevacizumab with bio...
Yoon-Koo Kang, MD, PhD, on Gastric/Gastroesophageal Junction Adenocarcinoma: Trial Results for T-DM1 vs a Taxane
Yoon-Koo Kang, MD, PhD, of the Asan Medical Center, discusses findings from this multicenter, phase II/III study of ado-trastuzumab emtansine vs a taxane in patients with previousl...
Eric Francois, MD, on Rectal Cancer: Findings From the ACCORD12 Trial
Eric Francois, MD, of the Centre Antoine-Lacassagne, discusses the 5-year follow-up results from this phase III study of neoadjuvant treatment in rectal cancer (Abstract 490). To v...
